Atorvastatin's market dominance was driven by a pivotal 1997 FDA rule change allowing direct-to-consumer ads. Pfizer's marketing team treated the drug not as a medical compound, but as a consumer product like Nike, creating massive patient-led demand.

Despite its first-mover advantage, Novo Nordisk lost its lead in the weight-loss drug market by failing to recognize its consumer-driven nature. While it planned a traditional pharma launch, competitor Eli Lilly adopted a direct-to-consumer model, treating the drug like an e-commerce product and capturing the market.

The two pharma giants are competing aggressively in the direct-to-consumer channel. They're cutting prices on their GLP-1 drugs, anticipating that lower costs will drive significantly higher volume and sales in the long run, even if it hurts short-term revenue forecasts.

Eli Lilly and Novo Nordisk's DTC programs for weight loss drugs give employers an alternative to point employees towards, providing cover to drop expensive insurance coverage and potentially reducing access for patients who rely on it.

The massive success of GLP-1s is not just about a $100B drug class. It's the first commercial proof that consumers are actively choosing preventative medicine, paving the way for a broader, trillion-dollar revolution in public health spending and behavior.

In an aggressive commercial move, Novo Nordisk partnered with telehealth company Hims to distribute its branded obesity drug. This is notable because Hims was recently reprimanded by the FDA for trying to sell a compounded version. Novo is turning a potential adversary into a distribution channel to maximize market reach.

According to Novo Nordisk's CEO and conference reporters, the ADA's annual meeting is now driven more by obesity research than its traditional focus on diabetes. This seismic shift reflects how the GLP-1 boom has reshaped R&D priorities and turned the conference into a key battleground for the weight-loss market.

In the UK, where direct drug advertising is illegal, Novo Nordisk used experiential marketing as a competitive tool. It created a large maze by the River Thames to raise general obesity awareness, engaging the public directly to gain mindshare against rival Eli Lilly without explicitly promoting its drug.

After lagging Eli Lilly in the injectable obesity drug market, Novo Nordisk has reversed the dynamic by successfully launching its oral version, Wagovi pill, first. This head start has given Novo a substantial lead in sales and prescriptions in the new oral segment, demonstrating how a shift in drug delivery format can completely reset a competitive landscape.